T-Cell Therapy (ECT204) in Adults With Advanced HCC
Status:
Recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
This is an open-label, dose escalation, multi-center, Phase I/II clinical trial aimed at
assessing the safety and preliminary efficacy of an investigational ARTEMIS® ECT204 T-cell
therapy. The trial is suitable for adult subjects (≥ 18 years of age) diagnosed with
GPC3-positive HCC, who have failed or not tolerated at least two (2) different anti-HCC
systemic agents.
Phase I has concluded and a Recommended Phase II Dose (RP2D) has been determined. We are now
conducting Phase II to further confirm the safety profile of ECT204 and evaluate its
efficacy.